ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/LSD1
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/LSD1
6
trial(s) found.
NCT06456346
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants (
3543-007
)
LSD1 inhibitor
antimetabolite
Essential thrombocythaemia
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06351631
Haem
Phase 3
Recruiting
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study (
3543-017
)
LSD1 inhibitor
Myelofibrosis
Polycythemia vera
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06079879
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea (
3543-006
)
LSD1 inhibitor
antimetabolite
Essential thrombocythaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12624000478516
Haem
Phase 1 / Phase 2
Not yet recruiting
Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis (
JBI-802-102
)
LSD1/HDAC6 inhibitor
Essential thrombocythaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Myeloproliferative Neoplasm
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05558696
Haem
Phase 2
Active not recruiting
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bomedemstat in Patients With Polycythemia Vera (PV) (
3543-004
)
LSD1 inhibitor
Polycythemia vera
VIC
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
ACTRN12623001006639
Advanced
Phase 1
Completed
An Open-Label, Phase 1 Study to Characterize the Effects of a Moderate CYP3A4 and P-glycoprotein Inhibitor on the Pharmacokinetics of Bomedemstat (IMG-7289) in Healthy Participants (
IMG-7289-CTP-107
)
LSD1 inhibitor
Cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Not yet recruiting (1)
Active not recruiting (1)
Completed (1)
Recruitment Country and State
SA (5)
WA (4)
NSW (3)
VIC (3)
NZ (2)
QLD (2)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (1)
Phase 3 (3)
Trial Type
Haem (5)
Advanced (1)
Cancer Therapy Class
LSD1
100%
JAK1
17%
JAK2
17%
HDAC6
17%
Facility
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
3168 - Clayton - Monash Medical Centre (3)
6000 - Perth - Royal Perth Hospital (3)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
NZ.0622 - Takapuna - North Shore Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Myeloproliferative neoplasm
Essential thrombocythaemia
Polycythemia vera
Myelofibrosis
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy